Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 195,600 shares, a drop of 14.2% from the August 31st total of 228,000 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average trading volume of 162,200 shares, the short-interest ratio is currently 1.2 days.

Institutional Trading of Bolt Biotherapeutics

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. Acuitas Investments LLC grew its stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 21.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 630,507 shares of the company’s stock after acquiring an additional 112,555 shares during the period. Acuitas Investments LLC owned about 1.65% of Bolt Biotherapeutics worth $473,000 at the end of the most recent reporting period. 86.70% of the stock is owned by institutional investors and hedge funds.

Bolt Biotherapeutics Price Performance

Shares of Bolt Biotherapeutics stock traded up $0.02 during trading on Monday, reaching $0.64. The company’s stock had a trading volume of 111,844 shares, compared to its average volume of 175,390. The business has a 50 day moving average price of $0.68 and a 200-day moving average price of $0.87. Bolt Biotherapeutics has a 12-month low of $0.55 and a 12-month high of $1.56. The company has a market capitalization of $24.36 million, a P/E ratio of -0.37 and a beta of 0.93. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.19.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, August 13th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.08). The company had revenue of $1.28 million for the quarter, compared to analysts’ expectations of $1.19 million. Bolt Biotherapeutics had a negative return on equity of 61.40% and a negative net margin of 592.57%. As a group, sell-side analysts anticipate that Bolt Biotherapeutics will post -1.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Thursday, August 15th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.